[CAS NO. 2445185-57-7]  MSC-4381

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2445185-57-7]

Catalog
HY-132301
Brand
MCE
CAS
2445185-57-7

DESCRIPTION [2445185-57-7]

Overview

MDL-
Molecular Weight537.97
Molecular FormulaC26H20ClN3O6S
SMILESO=C(C1=NC=C(C#CC2=CC(Cl)=CC=C2NS(=O)(C3=C4N=CC=CC4=C(OCC)C=C3)=O)C(OC)=C1)O

For research use only. We do not sell to patients.

Summary

MSC-4381 (MCT4-IN-1) is an orally active and selective monocarboxylate transporter 4 (MCT4/SLC16A3) inhibitor with an IC 50 of 77 nM and a K i of 11 nM. MSC-4381 targets to the cytosolic domain of MCT4 . MSC-4381 results in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells. MSC-4381 has the potential for MCT4 transporter inhibition research [1] .


IC50 & Target

MCT4

77 nM (IC 50 )

MCT4

11 nM (Ki)


In Vitro

MSC-4381 (compound 18n) inhibits lactate efflux in the MDA-MB-231 cell line with an IC 50 of 1 nM. The on-target activity is confirmed with a K i of 11 nM by fluorescence cross-correlation spectroscopy (FCCS) [1] .
MSC-4381 does not inhibit lactate efflux to a similar extent in SNU-398 and MiaPaca2, and only 600-fold less in RT-4 cell lines [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

MSC-4381 (compound 18n; 30 mg/kg; PO; single dose) only combined with MCT1/2 inhibitor exhibits a significant tumoral intracellular lactate accumulation [1] .
MSC-4381 (30 mg/kg/day; for 15 days) shows no significant antitumor activity [1] .
MSC-4381 (0.2 mg/kg; iv) has a T 1/2 of 1 hours, a CL of 0.33 L/h•kg, a C max of 489 ng/mL and a V ss of 0.4 L/kg for mice [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MC38 tumor-bearing C57/BL6 mice [1]
Dosage: 30 mg/kg
Administration: PO; single dose
Result: Only combined with MCT1/2 inhibitor exhibited a significant tumoral intracellular lactate accumulation.
Animal Model: Mice [1]
Dosage: 0.2 mg/kg (Pharmacokinetic Analysis)
Administration: IV
Result: Had a T 1/2 of 1 hours, a CL of 0.33 L/h•kg, a C max of 489 ng/mL and a V ss of 0.4 L/kg for mice.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL ( 154.90 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8588 mL 9.2942 mL 18.5884 mL
5 mM 0.3718 mL 1.8588 mL 3.7177 mL
10 mM 0.1859 mL 0.9294 mL 1.8588 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (3.87 mM); Clear solution

* All of the co-solvents are available by MCE.